Mesoblast (MESO) Cash from Operations Growth (1y) (2017 - 2023)
Mesoblast (MESO) Cash from Operations Growth (1y) (2017 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.58% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -119.28% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 100.14% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 151.70% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 56.79% |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -17.16% |
| Mar 31, 2023 | -5.04% |
| Dec 31, 2022 | 9.69% |
| Sep 30, 2022 | 21.50% |
| Jun 30, 2022 | 26.56% |
| Mar 31, 2022 | 36.78% |
| Dec 31, 2021 | 40.42% |
| Sep 30, 2021 | 35.39% |
| Jun 30, 2021 | -38.76% |
| Mar 31, 2021 | -23.00% |
| Dec 31, 2020 | -2,199.25% |
| Sep 30, 2020 | -81.05% |
| Jun 30, 2020 | 28.56% |
| Mar 31, 2020 | 6.11% |
| Dec 31, 2019 | -165.55% |
| Sep 30, 2019 | 20.40% |
| Jun 30, 2019 | 5.46% |
| Mar 31, 2019 | -8.09% |
| Dec 31, 2018 | 113.65% |
| Sep 30, 2018 | 3.99% |